AKI Advances: Biomarkers, Outcomes, and Clinical Trials
Back to course
Video Transcription
Video Summary
Asset Subtitle

Moderator(s): Jonathan Himmelfarb, David Leaf

Presentation(s):
  • Plasma Biomarkers of Kidney Tubule Health and Kidney Function Recovery After Ambulatory AKI in People with HIV - Merve Postalcioglu
  • proMoting Effective Renoprotection in Cardiac sURgery patients by Inhibition of SGLT2 (MERCURI-2): A Randomized Controlled Trial in People Undergoing Cardiac Surgery - Maartina Oosterom-Eijmael
  • Temporal Kinetics of Sepsis-Associated AKI Subphenotypes - Elizabeth Kiernan
  • Temporal Trends in AKI-Related Mortality Across 43 Countries, 1996-2021, with Projections up to 2050: A Global Time Series Analysis and Modelling Study - Jeong-Yeun Lee
  • Preoperative Biomarkers for Enrichment of Clinical Trials in Cardiac Surgery-Associated AKI: A TRIBE Cohort Secondary Analysis - Lee Goeddel
  • Reducing Mortality in Metformin-Associated Lactic Acidosis Through a Fast-Track Clinical Pathway: A Controlled Interrupted Time Series Quality Improvement Study - Watanyu Parapiboon
  • Preoperative Immunoneutralization of Endogenous Ouabain Lowers the Risk for AKI Evoked by Cardiac Bypass Graft Surgery - Mordecai Blaustein
  • Effects of Nephrotoxic Medication Combinations on Rates of Stage 2/3 AKI - Casey Hardin
  • Urinary CXCL9 as a Predictive Biomarker of Corticosteroid Responsiveness in Acute Tubulointerstitial Nephritis - Sagar Sadarangani

Note: Continuing education credits are not being offered for this session.
Meta Tag
Date 11/8/2025
Pathway 1 AKI and Critical Care
Session ID 519808
Keywords
acute kidney injury
AKI biomarkers
HIV ambulatory AKI
UMOD
KIM-1
TNFR1 TNFR2
dapagliflozin
cardiac surgery AKI
MERCURY-2 trial
sepsis-associated AKI subphenotypes
ANG2 ANG1 ratio
WHO global AKI mortality
urinary CXCL9